Prescribing proton pump inhibitors

Last month, the research round-up provided you with an overview looking at prescribing and management of the menopause. This month, we will review three articles on the prescribing of proton pump inhibitors (PPIs) across a range of areas. The first is a study examining prescribing trends in children in the UK. The second article is a systematic review of approaches to deprescribing of PPIs in clinical practice. Finally, in our third article we look at a review of the effects of PPIs on inflammatory bowel disease.

This article, published in the journal Pharmacoepidemiology and Drug Safety, sought to describe the prescribing trends of PPIs and H2 receptor antagonists (H2RAs) among children with gastroesophageal reflux in the UK between 1998 and 2019.

This study was conducted using a population-based retrospective methodology approach and included data over the time period of 1998–2019 collected from the Clinical Practice Research Datalink (CPRD) Aurum, a database comprising clinical data from over 19 million patients enrolled with around 70 general practices in the UK.